FrancophonIA/ELRC3.0 huggingface dataset:
English: Talk to your doctor or hospital pharmacist before receiving Pemetrexed Fresenius Kabi.
Slovenian: Pred začetkom uporabe zdravila Pemetreksed Fresenius Kabi se posvetujte z zdravnikom ali bolnišničnim farmacevtom.
English: The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of pemetrexed plus cisplatin first line induction treatment, the median investigator-assessed PFS was 6.9 months for the pemetrexed arm and 5.6 months for the placebo arm (hazard ratio = 0.59 95% CI =
Slovenian: Za naključno izbrane bolnike, merjeno od začetka zdravljenja s pemetreksedom in indukcijskim zdravljenjem prve izbire s cisplatinom, je bilo mediano preživetje brez napredovanja bolezni po oceni raziskovalca 6,9 meseca za vejo, ki je prejemala pemetreksed, in 5,6 meseca za vejo, ki je prejemala placebo (razmerje tveganja = 0,59, 95 % IZ = 0,47-0,74).
English: Common Leukocytes decreased
Slovenian: Znižani levkociti Znižani nevtrofilci
English: Very common
Slovenian: Zelo pogosti Izpuščaj
English: The active substance is pemetrexed.
Slovenian: Učinkovina je pemetreksed.
English: Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion
Slovenian: Pemetreksed Fresenius Kabi 500 mg prašek za koncentrat za raztopino za infundiranje
English: Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion
Slovenian: Pemetreksed Fresenius Kabi 100 mg prašek za koncentrat za raztopino za infundiranje
English: Common Vomiting Mucositis/ stomatitis
Slovenian: Stomatitis/ faringitis
English: Progression-free survival (months) ▪ Median ▪ HR (95% CI)
Slovenian: Preživetje brez napredovanja (meseci) • Mediana
English: Pemetrexed/ cisplatin (N = 839)
Slovenian: Pogostnost Dogodek** pemetreksed/cisplatin N = 839
English: Common Fever
Slovenian: Skupno preživetje
English: LIST OF EXCIPIENTS
Slovenian: pemetreksed docetaksel
English: Breastfeeding
Slovenian: Dispepsija
English: Grade
Slovenian: Dojenje
English: Inflammation of the lining of the oesophagus (gullet) has been experienced with Pemetrexed Fresenius Kabi / radiation therapy.
Slovenian: Nekateri bolniki so med zdravljenjem z zdravilom Pemetreksed Fresenius Kabi/obsevanjem doživeli vnetje sluznice požiralnika (grla).
English: Acute renal failure
Slovenian: Preživetje brez napredovanja
English: 19 January 2017 EMA/747766/2016
Slovenian: 19. januar 2017 EMA/747766/2016
English: • If you have any questions about your treatment, speak to your healthcare professional.
Slovenian: • Če imate kakršna koli vprašanja o zdravljenju, se posvetujte z zdravstvenim delavcem.
English: Information for patients and carers
Slovenian: Informacije za bolnike in negovalce
English: More information about Suliqua can be found on the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/human_ med_002064.jsp
Slovenian: Več informacij o zdravilu Suliqua je na voljo na spletni strani agencije: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/human_ med_002064.jsp
English: This could lead to fluctuations in blood glucose control.
Slovenian: To bi privedlo do nihanj v urejenosti krvnega sladkorja.
English: Suliqua is a medicine that is used for the treatment of type-2 diabetes.
Slovenian: Suliqua je zdravilo, ki se uporablja za zdravljenje sladkorne bolezni tipa 2.
English: Measures intended to reduce risk of confusion between two pens of different strengths
Slovenian: Ukrepi za zmanjšanje tveganja za zamenjavo peresnikov dveh različnih jakosti
English: • Ensure that patients and their caretakers are adequately informed on how to use their medicine.
Slovenian: • Poskrbite, da so bolniki in njihovi negovalci ustrezno seznanjeni s tem, kako morajo uporabljati zdravilo.
English: • When starting Suliqua and in the weeks thereafter you should measure your blood sugar levels more frequently than usual.
Slovenian: • Po začetku uporabe zdravila Suliqua in v tednih za tem si morate krvni sladkor meriti pogosteje kot običajno.
English: To reduce the risk of medication errors, educational materials will be sent out to relevant healthcare professionals in the EU where the product is marketed, to raise awareness about the differences between the two pens, the way the dose is expressed and how to use the medicine correctly.
Slovenian: Da bi zmanjšali tveganje za napake pri uporabi zdravila, bo izobraževalno gradivo poslano ustreznim zdravstvenim delavcem v EU, kjer se zdravilo trži, da bi tako povečali zavedanje o razlikah med peresnikoma, o načinu izražanja odmerka in pravilni uporabi zdravila.
English: Before you use Suliqua be clear on how many dose steps you require.
Slovenian: Pred uporabo zdravila Suliqua morate vedeti, koliko odmernih korakov potrebujete.
English: • You must therefore not use the pens interchangeably as you could receive too much or too little lixisenatide and this could disrupt the control of your blood sugar levels.
Slovenian: • Zato peresnikov ne smete zamenjevati, saj bi lahko prejeli preveč ali premalo liksisenatida, kar bi zmotilo urejenost vašega krvnega sladkorja.
English: Patients will receive a ‘patient guide' from their healthcare professional which they should read carefully along with the package leaflet.
Slovenian: Bolniki bodo od zdravstvenega delavca prejeli „vodnik za bolnike“, ki ga morajo pozorno prebrati, skupaj z navodilom za uporabo.
English: It is used for people needing 10-40 units of insulin daily.
Slovenian: Uporablja se pri bolnikih, ki potrebujejo 10-40 enot insulina na dan.
English: It is available as a solution for injection in pre-filled pens.
Slovenian: Na voljo je v obliki raztopine za injiciranje v napolnjenih peresnikih.
English: It is used together with diabetes medicines taken by mouth in adults whose blood glucose (sugar) levels are not satisfactorily controlled by metformin alone or metformin combined with either a glucose-lowering medicine or insulin.
Slovenian: Uporablja se skupaj z zdravili za zdravljenje sladkorne bolezni za peroralno uporabo pri odraslih, pri katerih raven glukoze (sladkorja) v krvi ni zadostno nadzorovana zgolj s samim metforminom ali metforminom v kombinaciji z zdravilom za zniževanje sladkorja ali insulinom.
English: Your healthcare professional will give you this information.
Slovenian: To vam bo povedal vaš zdravnik.
English: • Patients who are blind or with poor vision must be instructed to always get assistance from another person who has good vision and is trained in using the Suliqua pen device.
Slovenian: • Slepe ali slabovidne bolnike je treba poučiti, naj vedno poiščejo pomoč nekoga, ki dobro vidi in je usposobljen za uporabo peresnika zdravila Suliqua.
English: The doses of insulin and lixisenatide contained in increasing dose steps are given in the figure below:
Slovenian: Odmerki insulina in liksisenatida, vsebovani v naraščajočih odmernih korakih, so navedeni v spodnji preglednici:
English: Healthcare professionals and patients expected to use the diabetes medicine Suliqua will be given educational materials to ensure that the medicine is used correctly and prevent medication errors such as confusion between the two different strengths of the product.
Slovenian: Zdravstveni delavci in bolniki, za katere se pričakuje, da bodo uporabljali zdravilo Suliqua za zdravljenje sladkorne bolezni, bodo prejeli izobraževalno gradivo, ki bo zagotovilo, da se zdravilo uporablja pravilno, in preprečilo napake pri uporabi zdravila, kot je zamenjava dveh različnih jakosti zdravila.
English: Healthcare professionals should ensure that they train their patients on how to use Suliqua correctly.
Slovenian: Zdravstveni delavci morajo zagotoviti, da svoje bolnike usposobijo za pravilno uporabo zdravila Suliqua.
English: Pharmacists should also check that patients have been trained on how to use the pen.
Slovenian: Farmacevti naj preverijo tudi, da so bolniki usposobljeni za uporabo peresnika.
English: • As for similar medicines containing insulin with a non-insulin medicine, the dose is expressed in dose steps.
Slovenian: • Kot velja za podobna zdravila, ki vsebujejo insulin in neinsulinsko zdravilo, je odmerek izražen v odmernih korakih.
English: The lixisenatide strength is lower to ensure an adequate but not excessive dose in people requiring higher doses of insulin.
Slovenian: Jakost liksisenatida je manjša, da zagotovi ustrezen, a ne prevelik odmerek pri bolnikih, ki potrebujejo večje odmerke insulina.
English: • Because the two pens contain different concentrations of lixisenatide, the dose step of one pen is not equivalent to the dose step of the other.
Slovenian: • Ker peresnika vsebujeta različni koncentraciji liksisenatida, odmerni korak pri enem peresniku ni enakovreden odmernemu koraku pri drugem.
English: You must never use a syringe to remove the medicine from its pen as this may lead to dosing errors and serious harm.
Slovenian: Nikoli ne smete uporabljati injekcijske brizge za odstranjevanje zdravila iz peresnika, saj to lahko privede do napak pri uporabi zdravila in resnih negativnih posledic.
English: • Read the instructions in your package leaflet carefully before using your medicine.
Slovenian: • Pred uporabo svojega zdravila natančno preberite navodilo za uporabo.
English: As for similar combination medicines used for the treatment of diabetes, the dose of Suliqua is expressed in ‘dose steps', with each dose step corresponding to one unit of insulin plus a fixed amount of lixisenatide.
Slovenian: Kot velja za podobna kombinirana zdravila, ki se uporabljajo za zdravljenje sladkorne bolezni, se tudi odmerek zdravila Suliqua izraža v „odmernih korakih“, pri čemer vsak odmerni korak ustreza eni enoti insulina in nespremenljivi količini liksisenatida.
English: The lixisenatide strength is higher to ensure an adequate dose in people requiring lower doses of insulin.
Slovenian: Jakost liksisenatida je večja, da zagotovi ustrezen odmerek pri bolnikih, ki potrebujejo manjše odmerke insulina.
English: One dose step always contains one unit of insulin, regardless of the Suliqua pen being used.
Slovenian: En odmerni korak vedno vsebuje eno enoto insulina, ne glede na uporabljeni peresnik zdravila Suliqua.
English: • Suliqua is supplied in a pre-filled pen and must only be used with this device.
Slovenian: • Zdravilo Suliqua je na voljo v napolnjenem peresniku in ga je treba tudi uporabljati samo s peresnikom.
English: • Explain the design and features of the pen to the patient and if the patient has been transferred from another pen device, highlight the differences in design between the two devices to avoid confusion (focus on colour differentiation, warning statements on carton/label).
Slovenian: Če je bolnik prešel z drugega peresnika, poudarite razlike v zasnovi med njima, da ne pride do zamenjave (osredotočite se na razlike v barvi in opozorilne izjave na škatli/oznaki).
English: Your healthcare professional will train you on how to use the pen.
Slovenian: Zdravstveni delavec vas bo usposobil za uporabo peresnika.
English: • Tell patients to closely monitor their blood sugar levels when starting Suliqua and in the weeks thereafter.
Slovenian: • Bolnikom povejte, naj po začetku uporabe zdravila Suliqua in v tednih za tem skrbno spremljajo krvni sladkor.
English: Suliqua is available in two different pens:
Slovenian: Zdravilo Suliqua je na voljo v dveh peresnikih:
English: • Pharmacists should clarify with the prescriber any incomplete prescription.
Slovenian: • Farmacevti naj se v primeru pomanjkljivega recepta posvetujejo z zdravnikom.
English: The amount of lixisenatide per dose step however varies (0.50 micrograms per dose step for the 10-40 pen and 0.33 micrograms per dose step for the 30-60 pen).
Slovenian: Količina liksisenatida na odmerni korak je drugačna (0,50 mikrogramov na odmerni korak pri peresniku 10-40 in 0,33 mikrogramov na odmerni korak pri peresniku 30-60).
English: • Explain to your patient that the dose counter of the pen device shows the number of dose steps to be injected.
Slovenian: • Bolniku pojasnite, da števec odmerkov na peresniku prikazuje število odmernih korakov, ki si jih mora injicirati.
English: • Suliqua is a fixed combination of insulin glargine/lixisenatide available in two strengths:
Slovenian: • Zdravilo Suliqua je nespremenljiva kombinacija insulina glargin/liksisenatida, na voljo v dveh jakostih:
English: • Suliqua is given in dose steps which correspond to a set number of units of insulin plus a fixed amount of lixisenatide.
Slovenian: • Zdravilo Suliqua se daje v odmernih korakih, ki ustrezajo nastavljenemu številu enot insulina in nespremenljivemu odmerku liksisenatida.
English: • Pharmacists are encouraged to check that patients and carers are able to read the strength of Suliqua, the dose range of the pre-filled pen and the dose counter of the pen device before dispensing Suliqua.
Slovenian: • Farmacevtom priporočamo, da pred izdajo zdravila Suliqua preverijo, ali bolniki in negovalci lahko odčitajo jakost zdravila Suliqua, odmerni razpon na napolnjenem peresniku in števec odmerkov na peresniku.
English: A syringe must never be used to withdraw insulin glargine and lixisenatide from the pre-filled pen as this may lead to dosing errors and serious harm.
Slovenian: Za jemanje insulina glargin in liksisenatida iz napolnjenega peresnika se nikoli ne sme uporabljati injekcijska brizga, saj to lahko privede do napak pri uporabi zdravila in resnih negativnih posledic.
English: • Suliqua is supplied in two pre-filled pens:
Slovenian: • Zdravilo Suliqua je na voljo v dveh napolnjenih peresnikih:
English: • The dose counter of the pen device shows the number of dose steps to be injected.
Slovenian: • Števec odmerkov na peresniku prikazuje število odmernih korakov, ki si jih boste injicirali.
English: The prescription must state the type of pen to be used (either Suliqua 10-40 or Suliqua 30-60), the strength (i.e. insulin glargine 100 units/ml + lixisenatide 50 micrograms/ml or insulin glargine 100 units/ml + lixisenatide 33 micrograms/ml) and the number of dose steps to be administered.
Slovenian: Na receptu mora biti navedena vrsta peresnika (Suliqua 10-40 ali Suliqua 30-60), jakost (tj. insulin glargin 100 enot/ml + liksisenatid 50 mikrogramov/ml ali insulin glargin 100 enot/ml + liksisenatid 33 mikrogramov/ml) in število odmernih korakov, ki si jih mora bolnik injicirati.
English: deliver between 10 and 40 dose steps per day (and is also referred to as Suliqua 10-40).
Slovenian: s tem peresnikom lahko vnesemo med 30 in 60 odmernih korakov na dan (in se imenuje tudi zdravilo Suliqua 30-60).
English: One dose step always contains one unit of insulin plus a fixed amount of lixisenatide.
Slovenian: En odmerni korak vedno vsebuje eno enoto insulina in nespremenljivo količino liksisenatida.
English: Suliqua contains a combination of insulin glargine and a non-insulin medicine, lixisenatide.
Slovenian: Zdravilo Suliqua vsebuje kombinacijo insulina glargina in neinsulinskega zdravila liksisenatida.
English: • Provide patients with the patient guide prior to prescribing or dispensing Suliqua.
Slovenian: • Pred predpisovanjem ali izdajo zdravila Suliqua bolnikom priskrbite vodnik za bolnike.
English: • Suliqua contains insulin glargine and a non-insulin medicine, lixisenatide.
Slovenian: • Zdravilo Suliqua vsebuje insulin glargin in neinsulinsko zdravilo liksisenatid.
English: • Suliqua must only be used with its pre-filled pen.
Slovenian: • Zdravilo Suliqua smete uporabljati samo z napolnjenim peresnikom.
English: deliver between 30 and 60 dose steps per day (and is also referred to as Suliqua 30-60) Since the two pens contain different amounts of lixisenatide for each dose step, it is important that they are not used interchangeably as this would result in patients receiving too much or too little lixisenatide.
Slovenian: Ker peresnika vsebujeta različni količini liksisenatida na odmerni korak, je pomembno, da se ne zamenjujeta, saj bi bolniki tako prejeli preveč ali premalo liksisenatida.
English: − Suliqua 30-60 (containing insulin glargine 100 units/ml with lixisenatide 33 micrograms/ml)this pen can deliver between 30 and 60 dose steps per day.
Slovenian: − zdravilo Suliqua 30-60 (vsebuje insulin glargin 100 enot/ml z liksisenatidom 33 mikrogramov/ml) - s tem peresnikom se lahko vnese med 30 in 60 odmernih korakov na dan.
English: − Suliqua 10-40 (containing insulin glargine 100 units/ml with lixisenatide 50 micrograms/ml)this pen can deliver between 10 and 40 dose steps per day.
Slovenian: − zdravilo Suliqua 10-40 (vsebuje insulin glargin 100 enot/ml z liksisenatidom 50 mikrogramov/ml) - s tem peresnikom lahko vnesete med 10 in 40 odmernih korakov na dan.
English: It has been available in the EU since the 1950s.
Slovenian: V EU je na voljo od petdesetih let prejšnjega stoletja.
English: Further information on Xigduo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/xigduo.
Slovenian: Nadaljnje informacije o zdravilu Xigduo so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/xigduo.
English: What measures are being taken to ensure the safe and effective use of Xigduo?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xigduo?
English: Xigduo received a marketing authorisation valid throughout the EU on 16 January 2014.
Slovenian: Za zdravilo Xigduo je bilo 16. januarja 2014 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
English: • patients who are intoxicated with alcohol (drunkenness) or who regularly drink excessive amounts of alcohol.
Slovenian: • bolnikih z intoksikacijo z alkoholom (pijanih bolnikih) ali tistih, ki redno pijejo prekomerne količine alkohola.
English: The majority of these data had already been used in the authorisation of Forxiga.
Slovenian: Večino teh podatkov so že predložili v postopku za pridobitev dovoljenja za promet z zdravilom Forxiga.
English: The European Medicines Agency decided that Xigduo's benefits are greater than its risks and recommended that it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Xigduo večje od z njim povezanih tveganj, in priporočila, da se lahko odobri za uporabo v EU.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xigduo have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Xigduo upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Xigduo must not be used in:
Slovenian: Zdravilo Xigduo se ne sme uporabljati pri:
English: Side effects reported with Xigduo are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Xigduo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: As for all medicines, data on the use of Xigduo are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Xigduo stalno spremljajo.
English: Dapagliflozin has been authorised in the European Union (EU) as Forxiga since 2012;
Slovenian: Ta učinkovina je v Evropski uniji (EU) odobrena od leta 2012 kot zdravilo Forxiga;
English: Xigduo contains two different active substances, which work in different ways:
Slovenian: Zdravilo Xigduo vsebuje dve različni učinkovini, ki delujeta vsaka na svoj način:
English: An overview of Xigduo and why it is authorised in the EU
Slovenian: Pregled zdravila Xigduo in zakaj je odobreno v EU
English: Why is Xigduo authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Xigduo odobreno v EU?
English: What benefits of Xigduo have been shown in studies?
Slovenian: Kakšne koristi zdravila Xigduo so se pokazale v študijah?
English: Regarding its safety profile, this was considered similar to the safety profile of dapagliflozin.
Slovenian: Glede varnostnega profila zdravila je zaključila, da je podoben varnostnemu profilu dapagliflozina.
English: For further information about using Xigduo, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Xigduo glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Dapagliflozin in combination with metformin was evaluated in 6 main studies involving 3,200 adults with type 2 diabetes.
Slovenian: Dapagliflozin so v kombinaciji z metforminom ocenjevali v šestih glavnih študijah, v katerih je sodelovalo 3 200 odraslih s sladkorno boleznijo tipa 2.
English: Other information about Xigduo
Slovenian: Druge informacije o zdravilu Xigduo
English: • metformin works mainly by reducing glucose production and reducing its absorption from the gut.
Slovenian: • metformin deluje predvsem tako, da zavira tvorbo glukoze in zmanjšuje njeno absorpcijo v črevesju.
English: • on its own in patients whose disease is not controlled well enough with metformin alone;
Slovenian: • kot samostojno zdravilo pri bolnikih, pri katerih bolezni ni mogoče dovolj dobro uravnati samo z metforminom;
English: What is Xigduo and what is it used for?
Slovenian: Kaj je zdravilo Xigduo in za kaj se uporablja?
English: What are the risks associated with Xigduo?
Slovenian: Kakšna tveganja so povezana z zdravilom Xigduo?
English: • in combination with other diabetes medicines when these medicines together with metformin are not controlling the diabetes well enough.
Slovenian: • v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni, kadar ta zdravila v kombinaciji z metforminom zadostno ne uravnavajo bolezni.
English: • patients with diabetic precoma (a dangerous condition that can occur in diabetes);
Slovenian: • bolnikih z diabetično predkomo (nevarnim stanjem, ki se lahko pojavi pri sladkorni bolezni);
English: • patients with any form of acute metabolic acidosis (build up of acid in the blood), such as diabetic ketoacidosis (high blood levels of acids called ‘ketones') or lactic acidosis (build-up of lactic acid in the body);
Slovenian: • bolnikih s katero koli obliko akutne metabolične acidoze (kopičenja kisline v krvi), kot je diabetična ketoacidoza (visoke ravni kislin, imenovanih ketoni) ali laktacidoza (kopičenje mlečne kisline v telesu);
English: Xigduo can also be used to replace dapagliflozin and metformin taken as separate tablets.
Slovenian: Zdravilo Xigduo se lahko uporablja tudi za nadomestitev dapagliflozina in metformina v obliki ločenih tablet.
English: When Xigduo is added to treatment with insulin or a medicine that helps the body to produce insulin, such as a sulphonylurea, the doctor may need to lower the dose of insulin or sulphonylurea to prevent hypoglycaemia (low blood sugar levels).
Slovenian: Kadar se zdravilo Xigduo dodaja zdravljenju z insulinom ali zdravilom, ki telesu pomaga pri proizvodnji insulina, kot je sulfonilsečnina, bo moral zdravnik morda zmanjšati odmerek insulina ali sulfonilsečnine, da bi preprečil hipoglikemijo (nizke ravni sladkorja v krvi).
English: The most common side effects with Xigduo (which may affect more than 1 in 10 people) are hypoglycaemia (when used together with insulin or a sulphonylurea) and gastrointestinal symptoms (symptoms affecting the stomach and gut).
Slovenian: Najpogostejši neželeni učinki zdravila Xigduo (ki se lahko pojavijo pri več kot 1 bolniku od 10) so hipoglikemija (kadar se uporablja skupaj z insulinom ali sulfonilsečnino) in gastrointestinalni simptomi (simptomi, ki prizadenejo želodec in črevesje).
English: HbA1c (glycosylated haemoglobin) is a substance in the blood which gives an indication of how well the blood glucose is controlled.
Slovenian: HbA1c (glikozilirani hemoglobin) je snov v krvi, ki kaže, kako dobro je glukoza v krvi uravnavana.
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the amount of glucose (sugar) in the blood or when the body cannot use insulin effectively.
Slovenian: Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne proizvaja dovolj insulina za uravnavanje primerne ravni glukoze (sladkorja) v krvi ali pri kateri telo insulina ne more učinkovito izrabiti.